HISUN(SH:600267) Xin Lang Cai Jing·2025-12-12 08:52Core Viewpoint - Haizheng Pharmaceutical's wholly-owned subsidiary, Haizheng Hangzhou, has received a CEP certificate for Everolimus active pharmaceutical ingredient from EDQM, indicating the product's qualification for entry into the EU market, which will positively impact the company's international market expansion [1] Group 1 - Everolimus is applicable for various cancers and diseases related to tuberous sclerosis, and it can also prevent transplant rejection [1] - The global sales volume for Everolimus is projected to be approximately 128.81 kilograms in 2024, with an estimated 66.01 kilograms for the first half of 2025 [1] - The application for the CEP certificate was submitted on June 29, 2024, by Haizheng Hangzhou [1] Group 2 - The certification signifies the product's capability to enter international markets, which is expected to enhance the company's international business development [1] - However, there are risks associated with international business operations [1]